VISKAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Viskazide patents expire, and when can generic versions of Viskazide launch?
Viskazide is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in VISKAZIDE is hydrochlorothiazide; pindolol. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; pindolol profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VISKAZIDE?
- What are the global sales for VISKAZIDE?
- What is Average Wholesale Price for VISKAZIDE?
Summary for VISKAZIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| DailyMed Link: | VISKAZIDE at DailyMed |
US Patents and Regulatory Information for VISKAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VISKAZIDE | hydrochlorothiazide; pindolol | TABLET;ORAL | 018872-001 | Jul 22, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | VISKAZIDE | hydrochlorothiazide; pindolol | TABLET;ORAL | 018872-002 | Jul 22, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
